PlaqueTec’s BIOPATTERN trial passes 100 patients and expands to 8 NHS centers
PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to reveal the biological drivers of atherosclerotic cardiovascular disease (ASCVD), today announced that its BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist cardiac centers.
Read original article on The Medical News →Related news
-
What is 'food is medicine'? Two experts explain this decades‑old approach to health care that is taking on new life
United Kingdom
-
New surgical approaches aim to improve stomach cancer outcomes
United Kingdom
-
Study highlights healthcare barriers facing volunteer firefighters in Texas
United Kingdom
-
US sexual harassment reports increase sharply between 2018 and 2024
United Kingdom
-
Cervical cancer elimination is in reach—we just need more GP appointments
United Kingdom
-
Scientists unveil first comprehensive atlas of basal ganglia cell types
United Kingdom
-
ACC launches initiative to strengthen cardiovascular disease prevention
United Kingdom
-
Broad genomic testing linked to longer survival in advanced lung cancer, according to new study
United Kingdom